Clinical Trials Directory

Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer

This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Casodex (bicalutamide)
  • drug : Temsirolimus

Phase: Phase 1/Phase 2


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting

Footer Links: